HKSE:02289 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:02289 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Charmacy Pharmaceutical Co's Gross Profit for the six months ended in Jun. 2024 was HK$182 Mil. Charmacy Pharmaceutical Co's Revenue for the six months ended in Jun. 2024 was HK$2,527 Mil. Therefore, Charmacy Pharmaceutical Co's Gross Margin % for the quarter that ended in Jun. 2024 was 7.21%.
The historical rank and industry rank for Charmacy Pharmaceutical Co's Gross Margin % or its related term are showing as below:
During the past 10 years, the highest Gross Margin % of Charmacy Pharmaceutical Co was 7.13%. The lowest was 4.53%. And the median was 6.03%.
Charmacy Pharmaceutical Co had a gross margin of 7.21% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Charmacy Pharmaceutical Co was 1.60% per year.
The historical data trend for Charmacy Pharmaceutical Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charmacy Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial | 6.40 | 6.02 | 6.25 | 6.51 | 6.65 |
Charmacy Pharmaceutical Co Semi-Annual Data | ||||||||||||||||||||
Dec14 | Jun15 | Dec15 | Jun16 | Dec16 | Jun17 | Dec17 | Jun18 | Dec18 | Jun19 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | |
Gross Margin % | Get a 7-Day Free Trial | 6.59 | 6.44 | 6.27 | 7.05 | 7.21 |
For the Medical Distribution subindustry, Charmacy Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Distribution industry and Healthcare sector, Charmacy Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Charmacy Pharmaceutical Co's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Charmacy Pharmaceutical Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as
Gross Margin % (A: Dec. 2023 ) | = | Gross Profit (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 320.2 | / | 4816.601 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (4816.601 - 4496.404) | / | 4816.601 | |
= | 6.65 % |
Charmacy Pharmaceutical Co's Gross Margin for the quarter that ended in Jun. 2024 is calculated as
Gross Margin % (Q: Jun. 2024 ) | = | Gross Profit (Q: Jun. 2024 ) | / | Revenue (Q: Jun. 2024 ) |
= | 182.1 | / | 2526.847 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (2526.847 - 2344.712) | / | 2526.847 | |
= | 7.21 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Charmacy Pharmaceutical Co (HKSE:02289) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Charmacy Pharmaceutical Co had a gross margin of 7.21% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Charmacy Pharmaceutical Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jiangxi Pharmaceutical Investment Co., Limited | 2101 Beneficial owner | |
Jiang Yao Ji Tuan You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Jiang Xi Jiang Zhong Yi Yao Shang Ye Yun Ying You Xian Ze Ren Gong Si | 2201 Interest of corporation controlled by you | |
Yao Chuanglong | 2101 Beneficial owner | |
You Zeyan | 2202 Interest of your spouse | |
Guang Zhou Bai Yun Shan Yi Yao Ji Tuan Gu Fen You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Guang Zhou Yi Yao Ji Tuan You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Guang Yao Bai Yun Shan Xiang Gang You Xian Gong Si | 2101 Beneficial owner | |
Rays Capital Partners Limited | 2102 Investment manager | |
Ruan David Ching Chi | 2201 Interest of corporation controlled by you | |
Asian Equity Special Opportunities Portfolio Master Fund Limited | 2101 Beneficial owner | |
Wang Yonghui | 2101 Beneficial owner |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.